An observational study in Atrial Fibrillation, sponsored by The Cleveland Clinic. Recruiting at 2 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by The Cleveland Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Atrial Fibrillation by The Cleveland Clinic — 10 open to participants now, 11 under way, 1 of them phase 3. Atrial Fibrillation · The Cleveland Clinic.
Among the 26 studies in Atrial Fibrillation by The Cleveland Clinic, this one is the 5th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2025, is one of 13 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 24th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →10 of the 26 studies in Atrial Fibrillation by The Cleveland Clinic are open now, in 1 country. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 18–85
The Cleveland Clinic · Sites in United States
Ages 18–80
The Cleveland Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is below the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 90 across the 13 interventional studies, 60 across the 13 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
The Cleveland Clinic is the lead sponsor of 832 studies on the registry; 119 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.
4 of the studies in Atrial Fibrillation by The Cleveland Clinic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07893275Phase 3The Cleveland ClinicSGB for Prevention of Postop A-Fib After Cardiac SurgeryTrial | 2027-10 |
| NCT07087587The Cleveland ClinicSleep Apnea Triggers of Atrial Fibrillation: N-of-1 Randomized Control Trial (SPARTA): | 2026-12-31 |
| NCT06802081The Cleveland ClinicTIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation | 2026-12-31 |
| NCT07083115The Cleveland ClinicDeveloping MRI Technologies for Atrial Fibrillation | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 26 studies in Atrial Fibrillation by The Cleveland Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective multicenter clinical study comparing the efficacy of the Apple Watch AFib History tool to the iRhythm Zio Patch monitoring device in quantifying atrial fibrillation (AF) burden after surgical ablation. Patients with AF and mitral valve (MV) disease who undergo a Cox-Maze IV procedure concomitant to MV surgery will be evaluated at serial timepoints for up to 1 year postoperatively. The trial will be conducted in the United States at the Cleveland Clinic in Cleveland, OH and at the Washington University School of Medicine in St. Louis, MO.
The primary aim of this study is to evaluate the accuracy of current wearable technology using the Apple Watch AFib History tool, relative to ambulatory electrocardiogram (ECG) monitoring using the Zio Patch, for quantifying AF burden after surgical ablation. AF burden will be measured as a weekly estimate, defined as the percentage of time in AF over the prior seven consecutive days. This assessment will occur at 3 months, 6 months, and 1 year postoperatively.
This is a paired study design in which each subject will receive both the investigational device (Apple Watch) and reference device (Zio Patch) concurrently. The study population includes adults over the age of 22 years with a documented history of AF and MV disease undergoing elective MV surgery with concomitant Cox-Maze IV surgical ablation. All participants must be able to provide informed consent and adhere to the study follow-up schedule. Participants who meet the eligibility criteria will be enrolled on a rolling basis. Pre-surgical questionnaires, including Patient-Reported Outcomes Measurement Information System (PROMIS-10), MacNew, and Atrial Fibrillation Severity Scale (AFSS) surveys will be implemented at baseline and serial follow-up.
The monitoring period will be conducted in phases during serial follow-up at 1 month, 3 months, 6 months, and 1 year postoperatively. The Apple Watch will be worn postoperatively for the study duration. Participants will be instructed to charge the device overnight. The Zio Patch 14-day ambulatory ECG monitor will be applied at the following study timepoints: 3 months, 6 months, and 1 year postoperatively. Participants will be instructed to wear the Apple Watch concurrently during Zio Patch monitoring periods, as well as in the interval between visits.
At each follow-up visit (1 month, 3 months, 6 months, and 1 year), participants will undergo standardized evaluations, including a physical exam and the administration of the same standardized questionnaires. Comparative data from the Apple Watch and Zio Patch will be analyzed at the 3 months, 6 months, and 1 year visits.
Adult patients (>22 years) with a documented history of atrial fibrillation and mitral valve disease who undergo surgical ablation with a Cox-Maze IV concomitant to elective mitral valve surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Apple Watch AFib History feature uses PPG pulse rhythm data to detect and quantify the burden of atrial fibrillation.
Also known as: Apple Watch Series 10, Photoplethysmography (PPG) Pulse Rhythm Monitoring
The 14-day Zio Patch monitoring device (iRhythm Technologies, Inc., San Francisco, CA) uses continuous ambulatory ECG monitoring to quantify the burden of atrial fibrillation.
Also known as: iRhythm Zio Patch, Continuous Ambulatory ECG Monitoring
Accuracy of AF burden
This will be measured by comparing the weekly AF burden estimates from the Apple Watch AF History feature to the Zio Patch ambulatory ECG monitoring device. Weekly AF burden is defined as the percentage of time in AF over the prior seven consecutive days and will be measured at 3 months, 6 months, and 1 year postoperatively.
Time frame: From enrollment to 1 year postoperatively
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 30 months is below that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.